Indications

We focus on rare respiratory diseases in order to give patients with unmet medical needs better treatment options.

Read more

Pipeline

We are advancing a pipeline of novel inhalation therapies for the treatment of severe pulmonary conditions.

Read more

Clinical trials

Savara is currently conducting clinical trials within the fields of cystic fibrosis (CF) and pulmonary alveolar proteinosis (PAP).

Read more

AeroVanc.com

Visit the AeroVanc website to learn more about MRSA in Cystic Fibrosis, AeroVanc and our upcoming Phase III clinical study

Read more

aerovanc

PAP.Info

Visit our PAP portal for patients and relatives and connect across borders

Read more

papinfo

News & Events

07Jan, 2017

Mast Therapeutics and Savara sign merger agreement

0 Comments
Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call Scheduled... Read More
02Nov, 2016

Savara Pharmaceuticals appoints David L. Lowrance as CFO

0 Comments
Austin, Texas – November 2, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More
Back to Top